{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T17:31:57Z","timestamp":1790875917685,"version":"4.1.0"},"reference-count":31,"publisher":"American Society of Hematology","issue":"9","license":[{"start":{"date-parts":[[2022,5,11]],"date-time":"2022-05-11T00:00:00Z","timestamp":1652227200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/legalcode"}],"content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,9,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Patients aged &amp;lt;65 years with peripheral T-cell lymphoma (PTCL) are treated with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP). Although the addition of etoposide (CHOEP) and consolidation with autologous stem cell transplantation (ASCT) are preferred in some countries, randomized trials are lacking. This nationwide population-based study assessed the impact of etoposide and ASCT on overall survival (OS) among patients aged 18 to 64 years with stage II to IV anaplastic large-cell lymphoma (ALCL), angioimmunoblastic T-cell lymphoma (AITL), or PTCL not otherwise specified (NOS) diagnosed between 1989 and 2018 using the Netherlands Cancer Registry. Patients were categorized into 2 calendar periods, representing pre- and post-eras of etoposide and ASCT, respectively. A total of 1427 patients were identified (ALCL, 35%; AITL, 21%; and PTCL NOS, 44%). OS increased from 39% in the period from 1989 to 2009 to 49% in the period of 2009 to 2018 (P &amp;lt; .01). Five-year OS was superior for patients treated with CHOEP vs CHOP (64% and 44%, respectively; P &amp;lt; .01). When adjusted for subtype, International Prognostic Index score, and ASCT, the risk of mortality was similar between the 2 groups, except for patients with ALK+ ALCL, for whom the risk of mortality was 6.3 times higher when treated with CHOP vs CHOEP. Patients undergoing consolidation with ASCT had superior 5-year OS of 81% compared with 39% for patients not undergoing ASCT (P &amp;lt; .01), regardless of whether complete remission was achieved. In patients aged &amp;lt;65 years with advanced-stage ALK\u2212 ALCL, AITL, or PTCL, the use of ASCT consolidation, but not the addition of etoposide, was associated with improved OS.<\/jats:p>","DOI":"10.1182\/blood.2021015114","type":"journal-article","created":{"date-parts":[[2022,5,11]],"date-time":"2022-05-11T18:10:58Z","timestamp":1652292658000},"page":"1009-1019","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":76,"title":["Impact of etoposide and ASCT on survival among patients aged &amp;lt;65 years with stage II to IV PTCL: a population-based cohort study"],"prefix":"10.1182","volume":"140","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6014-4810","authenticated-orcid":false,"given":"Mirian","family":"Brink","sequence":"first","affiliation":[{"name":"1Department of Research and Development, Netherlands Comprehensive Cancer Organization, Utrecht, The Netherlands;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederik O.","family":"Meeuwes","sequence":"additional","affiliation":[{"name":"2Department of Hematology, Martini Hospital, Groningen, The Netherlands;"},{"name":"3Department of Hematology, University Medical Center Groningen, Groningen, The Netherlands;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marjolein W. M.","family":"van der Poel","sequence":"additional","affiliation":[{"name":"4Division of Hematology, Department of Internal Medicine, GROW School for Oncology and Developmental Biology, Maastricht University Medical Center, Maastricht, The Netherlands;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie Jos\u00e9","family":"Kersten","sequence":"additional","affiliation":[{"name":"5Department of Hematology, Amsterdam University Medical Center, Amsterdam, The Netherlands;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mari\u00eblle","family":"Wondergem","sequence":"additional","affiliation":[{"name":"5Department of Hematology, Amsterdam University Medical Center, Amsterdam, The Netherlands;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pim G. N. J.","family":"Mutsaers","sequence":"additional","affiliation":[{"name":"6Department of Hematology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lara H.","family":"B\u00f6hmer","sequence":"additional","affiliation":[{"name":"7Department of Hematology, Haga Hospital, The Hague, The Netherlands;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7840-6156","authenticated-orcid":false,"given":"F. J. Sherida H.","family":"Woei-A-Jin","sequence":"additional","affiliation":[{"name":"8Department of General Medical Oncology, University Hospitals Leuven, Leuven, Belgium;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Otto","family":"Visser","sequence":"additional","affiliation":[{"name":"9Department of Hematology, Isala Hospital, Zwolle, The Netherlands;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3650-4588","authenticated-orcid":false,"given":"Rimke","family":"Oostvogels","sequence":"additional","affiliation":[{"name":"10Department of Hematology, University Medical Center Utrecht, Utrecht, The Netherlands; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patty M.","family":"Jansen","sequence":"additional","affiliation":[{"name":"11Department of Pathology and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9828-9460","authenticated-orcid":false,"given":"Wouter","family":"Plattel","sequence":"additional","affiliation":[{"name":"3Department of Hematology, University Medical Center Groningen, Groningen, The Netherlands;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerwin A.","family":"Huls","sequence":"additional","affiliation":[{"name":"3Department of Hematology, University Medical Center Groningen, Groningen, The Netherlands;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1628-6256","authenticated-orcid":false,"given":"Joost S. P.","family":"Vermaat","sequence":"additional","affiliation":[{"name":"12Department of Hematology, Leiden University Medical Center, Leiden, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2740-2873","authenticated-orcid":false,"given":"Marcel","family":"Nijland","sequence":"additional","affiliation":[{"name":"3Department of Hematology, University Medical Center Groningen, Groningen, The Netherlands;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"key":"2022090115232501100_B1","volume-title":"World Cancer Report 2014.","author":"Stewart","year":"2014"},{"issue":"10","key":"2022090115232501100_B2","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1182\/blood-2014-04-573089","article-title":"Real-world data on prognostic factors and treatment in peripheral T-cell lymphomas: a study from the Swedish Lymphoma Registry","volume":"124","author":"Ellin","year":"2014","journal-title":"Blood."},{"issue":"25","key":"2022090115232501100_B3","doi-asserted-by":"crossref","first-page":"4124","DOI":"10.1200\/JCO.2008.16.4558","article-title":"International peripheral T-cell and natural killer\/T-cell lymphoma study: pathology findings and clinical outcomes","volume":"26","author":"Vose","year":"2008","journal-title":"J Clin Oncol."},{"key":"2022090115232501100_B4","first-page":"345","volume-title":"WHO Classification of Tumours of Hematopoietic and Lymphoid Tissues.","author":"Swerdlow","year":"2017","edition":"Revised 4th ed"},{"issue":"5","key":"2022090115232501100_B5","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1111\/bjh.13202","article-title":"Factors predicting survival in peripheral T-cell lymphoma in the USA: a population-based analysis of 8802 patients in the modern era","volume":"168","author":"Petrich","year":"2015","journal-title":"Br J Haematol."},{"issue":"2","key":"2022090115232501100_B6","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1002\/ajh.25674","article-title":"Incidence and outcomes of rare T cell lymphomas from the T Cell Project: hepatosplenic, enteropathy associated and peripheral gamma delta T cell lymphomas","volume":"95","author":"Foss","year":"2020","journal-title":"Am J Hematol."},{"issue":"32","key":"2022090115232501100_B7","doi-asserted-by":"crossref","first-page":"3939","DOI":"10.1200\/JCO.2012.42.2345","article-title":"Long-term outcome of adults with systemic anaplastic large-cell lymphoma treated within the Groupe d\u2019Etude des Lymphomes de l\u2019Adulte trials","volume":"30","author":"Sibon","year":"2012","journal-title":"J Clin Oncol."},{"issue":"10","key":"2022090115232501100_B8","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1093\/annonc\/mdh392","article-title":"Characterization of peripheral T-cell lymphomas in a single North American institution by the WHO classification","volume":"15","author":"Savage","year":"2004","journal-title":"Ann Oncol."},{"issue":"12","key":"2022090115232501100_B9","doi-asserted-by":"crossref","first-page":"2815","DOI":"10.1080\/10428194.2017.1300888","article-title":"Outcome of peripheral T-cell lymphoma in first complete remission: a Danish-Swedish population-based study","volume":"58","author":"Cederleuf","year":"2017","journal-title":"Leuk Lymphoma."},{"issue":"16","key":"2022090115232501100_B10","doi-asserted-by":"crossref","first-page":"1970","DOI":"10.1200\/JCO.2012.44.7524","article-title":"Survival of patients with peripheral T-cell lymphoma after first relapse or progression: spectrum of disease and rare long-term survivors","volume":"31","author":"Mak","year":"2013","journal-title":"J Clin Oncol."},{"issue":"3","key":"2022090115232501100_B11","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1182\/blood-2003-06-2095","article-title":"Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: results of the NHL-B2 trial of the DSHNHL","volume":"104","author":"Pfreundschuh","year":"2004","journal-title":"Blood."},{"issue":"18","key":"2022090115232501100_B12","doi-asserted-by":"crossref","first-page":"3418","DOI":"10.1182\/blood-2010-02-270785","article-title":"Treatment and prognosis of mature T-cell and NK-cell lymphoma: an analysis of patients with T-cell lymphoma treated in studies of the German High-Grade Non-Hodgkin Lymphoma Study Group","volume":"116","author":"Schmitz","year":"2010","journal-title":"Blood."},{"issue":"5","key":"2022090115232501100_B13","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1111\/bjh.14740","article-title":"The addition of etoposide to CHOP is associated with improved outcome in ALK+ adult anaplastic large cell lymphoma: a Nordic Lymphoma Group study","volume":"178","author":"Cederleuf","year":"2017","journal-title":"Br J Haematol."},{"key":"2022090115232501100_B14","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.2147\/OTT.S189825","article-title":"Comparison of CHOP vs CHOPE for treatment of peripheral T-cell lymphoma: a meta-analysis","volume":"12","author":"Deng","year":"2019","journal-title":"OncoTargets Ther."},{"issue":"1","key":"2022090115232501100_B15","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1200\/JCO.2008.17.4870","article-title":"Autologous stem-cell transplantation as first-line therapy in peripheral T-cell lymphomas: results of a prospective multicenter study","volume":"27","author":"Reimer","year":"2009","journal-title":"J Clin Oncol."},{"issue":"3","key":"2022090115232501100_B16","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1093\/ije\/22.3.369","article-title":"Completeness of cancer registration in Limburg, The Netherlands","volume":"22","author":"Schouten","year":"1993","journal-title":"Int J Epidemiol."},{"issue":"4","key":"2022090115232501100_B17","doi-asserted-by":"crossref","first-page":"525","DOI":"10.3324\/haematol.2014.107300","article-title":"Trends in incidence, treatment and survival of aggressive B-cell lymphoma in the Netherlands 1989-2010","volume":"100","author":"Issa","year":"2015","journal-title":"Haematologica."},{"issue":"25","key":"2022090115232501100_B18","doi-asserted-by":"crossref","first-page":"3093","DOI":"10.1200\/JCO.2011.40.2719","article-title":"Up-front autologous stem-cell transplantation in peripheral T-cell lymphoma: NLG-T-01","volume":"30","author":"d\u2019Amore","year":"2012","journal-title":"J Clin Oncol."},{"issue":"7","key":"2022090115232501100_B19","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1002\/cncr.30416","article-title":"A prospective cohort study of patients with peripheral T-cell lymphoma in the United States","volume":"123","author":"Carson","year":"2017","journal-title":"Cancer."},{"issue":"9","key":"2022090115232501100_B20","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1002\/cncr.31861","article-title":"The role of autologous stem cell transplantation in patients with nodal peripheral T-cell lymphomas in first complete remission: report from COMPLETE, a prospective, multicenter cohort study","volume":"125","author":"Park","year":"2019","journal-title":"Cancer."},{"issue":"3","key":"2022090115232501100_B21","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1093\/annonc\/mdx787","article-title":"Role of up-front autologous stem-cell transplantation in peripheral T-cell lymphoma for patients in response after induction: an analysis of patients from LYSA centers","volume":"29","author":"Fossard","year":"2018","journal-title":"Ann Oncol."},{"issue":"5","key":"2022090115232501100_B22","doi-asserted-by":"crossref","first-page":"e190","DOI":"10.1016\/S2352-3026(18)30039-5","article-title":"CHOP versus GEM-P in previously untreated patients with peripheral T-cell lymphoma (CHEMO-T): a phase 2, multicentre, randomised, open-label trial","volume":"5","author":"Gleeson","year":"2018","journal-title":"Lancet Haematol."},{"issue":"1","key":"2022090115232501100_B23","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1038\/s41375-020-0838-5","article-title":"Alemtuzumab plus CHOP versus CHOP in elderly patients with peripheral T-cell lymphoma: the DSHNHL2006-1B\/ACT-2 trial","volume":"35","author":"Wulf","year":"2021","journal-title":"Leukemia."},{"key":"2022090115232501100_B24","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2020-134440","article-title":"Final analysis of the Ro-CHOP phase III study (conducted by LYSA): romidepsin plus CHOP in patients with peripheral T-cell lymphoma [abstract]","volume":"136","author":"Bachy","year":"2020","journal-title":"Blood."},{"issue":"3","key":"2022090115232501100_B25","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1182\/blood-2018-01-791335","article-title":"Allogeneic hematopoietic stem cell transplantation for T-cell lymphomas","volume":"132","author":"Schmitz","year":"2018","journal-title":"Blood."},{"issue":"9","key":"2022090115232501100_B26","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.1038\/leu.2014.79","article-title":"Intensified chemo-immunotherapy with or without stem cell transplantation in newly diagnosed patients with peripheral T-cell lymphoma","volume":"28","author":"Corradini","year":"2014","journal-title":"Leukemia."},{"issue":"1","key":"2022090115232501100_B27","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/s13045-020-00892-4","article-title":"Allogeneic stem cell transplantation for peripheral T cell lymphomas: a retrospective study in 285 patients from the Soci\u00e9t\u00e9 Francophone de Greffe de Moelle et de Th\u00e9rapie Cellulaire (SFGM-TC)","volume":"13","author":"Mamez","year":"2020","journal-title":"J Hematol Oncol."},{"issue":"19","key":"2022090115232501100_B28","first-page":"2646","article-title":"A randomized phase 3 trial of autologous vs allogeneic transplantation as part of first-line therapy in poor-risk peripheral T-NHL","volume":"137","author":"Schmitz","year":"2021","journal-title":"Blood."},{"issue":"10168","key":"2022090115232501100_B29","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/S0140-6736(18)32984-2","article-title":"Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial","volume":"393","author":"Horwitz","year":"2019","journal-title":"Lancet."},{"issue":"26","key":"2022090115232501100_B30","doi-asserted-by":"crossref","first-page":"2339","DOI":"10.1182\/blood.2019001821","article-title":"Brentuximab vedotin in the treatment of CD30+ PTCL","volume":"134","author":"Barta","year":"2019","journal-title":"Blood."},{"key":"2022090115232501100_B31","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1182\/blood-2019-122781","article-title":"An exploratory analysis of brentuximab vedotin plus CHP (A+CHP) in the frontline treatment of patients with CD30+ peripheral T-cell lymphomas (ECHELON-2): impact of consolidative stem cell transplant [abstract]","volume":"134","author":"Savage","year":"2019","journal-title":"Blood."}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/140\/9\/1009\/1917700\/bloodbld2021015114.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/140\/9\/1009\/1917700\/bloodbld2021015114.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T15:24:52Z","timestamp":1662045892000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/140\/9\/1009\/485214\/Impact-of-etoposide-and-ASCT-on-survival-among"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,1]]},"references-count":31,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2022,9,1]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2021015114","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,1]]}}}